Alone at the top
Before we get into the outstanding results released by Insulet we have to gloat just a little with the results released by Teladoc. This from an article posted on Healthcare Drive
“Teladoc Health reported a historic net loss in 2022 of $13.7 billion off revenue of $2.4 billion, mostly from an impairment charge related to the shrinking value of its Livongo acquisition.”
Long ago we predicted that one of two things would happen either Livongo would get bought or it would be the greatest short of all time. Well, it turns out we were right twice. Teladoc foolishly . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.